Tandem Diabetes Care (TNDM) Change in Receivables (2013 - 2026)

Tandem Diabetes Care has reported Change in Receivables for 14 years, with the latest figure at -$22.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 309.17% year-over-year to -$22.7 million; the trailing twelve-month figure through Mar 2026 stood at $23.3 million (down 43.75% YoY), and the FY2025 full-year result was $56.8 million, up 173.2% from the prior year.
• Change in Receivables for Q1 2026 stood at -$22.7 million, down from $42.0 million in the prior quarter.
• The five-year high for Change in Receivables was $42.0 million in Q4 2025, with the low at -$22.8 million in Q1 2023.
• Historically, Change in Receivables has averaged $3.4 million across 5 years, with a median of $5.6 million in 2023.
• Annual changes were most pronounced in 2025 — Change in Receivables soared 247.71% — and 2026, when it plunged 309.17%.
• Tandem Diabetes Care's Change in Receivables stood at $3.0 million in 2022, then surged by 84.41% to $5.6 million in 2023, then soared by 115.96% to $12.1 million in 2024, then soared by 247.71% to $42.0 million in 2025, then slumped by 153.98% to -$22.7 million in 2026.
• The last three Change in Receivables figures came in at -$22.7 million (Q1 2026), $42.0 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.